My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ:PEPG)

5.880 +3.220 (+121.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PepGen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG
From Pomerantz LLP
Via GlobeNewswire
PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit With Faruqi & Faruqi, LLP
From Faruqi & Faruqi, LLP
Via Business Wire
PEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against PepGen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
From Faruqi & Faruqi LLP
Via GlobeNewswire
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Urges PepGen Inc. (NASDAQ: PEPG) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG
From Pomerantz LLP
Via GlobeNewswire
Why Rent the Runway Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety. 
Via Benzinga
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
From PepGen Inc.
Via Business Wire
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
From PepGen Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
Traders are paying attention to the gapping stocks in Tuesday's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
From PepGen Inc.
Via Business Wire
PepGen Announces Appointment of Two New Directors to its Board
From PepGen Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From PepGen Inc.
Via Business Wire
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy. 
Via Benzinga
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
From PepGen Inc.
Via Business Wire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.